Universal CD7-targeted CAR T-cell therapy in T-ALL: a promising bridge to transplant, but not without caveats—a critical reappraisal - Takeaways - MDSpire

Universal CD7-targeted CAR T-cell therapy in T-ALL: a promising bridge to transplant, but not without caveats—a critical reappraisal

  • By

  • Qinghua Ke

  • Shiqiong Zhou

  • June 11, 2026

  • 0 min

Share

  • 1

    The phase 1 study demonstrates that BE-CAR7 can induce morphologic remission in heavily pretreated T-ALL patients.

  • 2

    An 82% rate of successful bridging to HSCT was observed, but BE-CAR7 is not intended as a definitive cure.

  • 3

    The study's small cohort of 11 patients limits conclusions about long-term efficacy and durability of remission.

  • 4

    Persistent cytopenias and viral reactivations were common, raising concerns about the toxicity of the treatment regimen.

  • 5

    Base editing's long-term safety remains uncertain, necessitating further trials to assess its clinical viability.

Original Source(s)

Universal CD7-targeted CAR T-cell therapy in T-ALL: a promising bridge to transplant, but not without caveats—a critical reappraisal

  • by Qinghua Ke, Shiqiong Zhou

  • June 11, 2026

Related Content

The future of neurosurgical oncology lies in cognitive neurosciences: understanding brain processing is much more valuable than surgical technology

Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease

Effectiveness of nurse-led dietary modification recommendations in the management of defecation dysfunction among patients with rectal cancer after sphincter-saving surgery: a scoping review